Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Liquidia Co. stock logo
LQDA
Liquidia
$12.95
-1.7%
$14.67
$5.71
$16.99
$984.59M0.16940,740 shs1.16 million shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.43
+1.2%
$3.87
$1.79
$5.38
$56.22M0.91148,280 shs70,770 shs
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$0.54
+1.9%
$0.50
$0.26
$1.14
$18.93M1.5832,526 shs7,504 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.86
+3.2%
$3.89
$1.03
$5.07
$115.72M2.44185,544 shs41,464 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Liquidia Co. stock logo
LQDA
Liquidia
-0.83%-3.65%-21.22%+7.59%+89.91%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
+3.04%+5.94%-10.08%+0.89%-31.52%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-2.75%+13.98%+6.43%+2.71%-53.10%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-1.58%-10.10%-11.58%+11.64%+70.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Liquidia Co. stock logo
LQDA
Liquidia
2.1186 of 5 stars
3.31.00.00.01.94.20.6
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.9077 of 5 stars
3.55.00.00.01.80.81.3
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
0.9244 of 5 stars
2.03.00.00.02.61.70.6
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.2452 of 5 stars
3.33.00.00.00.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Liquidia Co. stock logo
LQDA
Liquidia
2.60
Moderate Buy$21.0062.16% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$7.50118.66% Upside
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/A$3.80603.70% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00107.25% Upside

Current Analyst Ratings

Latest LQDA, SSKN, STIM, and SRTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
4/1/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/14/2024
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
2/21/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Liquidia Co. stock logo
LQDA
Liquidia
$17.49M56.29N/AN/A$0.73 per share17.74
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$24.41M2.30$0.06 per share56.97$2.98 per share1.15
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$33.36M0.57N/AN/A$0.37 per share1.46
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.62N/AN/A$1.18 per share3.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$490K$0.03114.37N/A1.99%1.04%0.93%5/9/2024 (Confirmed)
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-$10.83M-$0.31N/AN/AN/A-32.47%-52.50%-17.66%5/20/2024 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)

Latest LQDA, SSKN, STIM, and SRTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-$0.04N/A+$0.04N/AN/AN/A  
3/27/2024Q4 2023
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/A-$0.04-$0.04$0.03N/A$8.69 million
3/13/2024Q4 2023
Liquidia Co. stock logo
LQDA
Liquidia
-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    
2/8/2024Q4 2023
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.12$0.26+$0.14$0.26$12.10 million$12.57 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Liquidia Co. stock logo
LQDA
Liquidia
N/A
4.85
4.85
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
11.76
8.23
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.19
1.28
1.06
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
32.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Liquidia Co. stock logo
LQDA
Liquidia
31.60%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
11.10%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
40.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Liquidia Co. stock logo
LQDA
Liquidia
14576.03 million52.00 millionOptionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3516.39 million14.57 millionOptionable
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
9935.06 million20.89 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.04 millionOptionable

LQDA, SSKN, STIM, and SRTS Headlines

SourceHeadline
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM
New Study Offers Hope for Depression Patients Undergoing TMS TherapyNew Study Offers Hope for Depression Patients Undergoing TMS Therapy
msn.com - April 12 at 1:57 AM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
globenewswire.com - April 10 at 8:31 AM
Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)
marketbeat.com - April 6 at 7:36 PM
Neuronetics Stock (NASDAQ:STIM), Quotes and News SummaryNeuronetics Stock (NASDAQ:STIM), Quotes and News Summary
benzinga.com - April 5 at 5:38 AM
Neuronetics (STIM) FDA-Cleared NeuroStar to Aid in DepressionNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
zacks.com - April 1 at 11:56 AM
Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires
msn.com - April 1 at 1:05 AM
Neurostar cleared for use in adolescent depressionNeurostar cleared for use in adolescent depression
bioworld.com - March 29 at 12:15 AM
FDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatmentFDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatment
medicaldialogues.in - March 29 at 12:15 AM
FDA Clears NeuroStars TMS Therapy for Adolescents with Major Depressive DisorderFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
msn.com - March 29 at 12:15 AM
Neuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM) Short Interest Update
marketbeat.com - March 28 at 11:57 AM
Neuronetics wins FDA clearance for device to treat adolescents with depressionNeuronetics wins FDA clearance for device to treat adolescents with depression
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 27 at 4:30 PM
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
markets.businessinsider.com - March 27 at 6:41 AM
Neuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionNeuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
fiercebiotech.com - March 27 at 6:41 AM
Neuronetics (STIM) "Market Perform" Rating Reiterated at William BlairNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blair
marketbeat.com - March 26 at 3:29 PM
TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent DepressionTMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depression
empr.com - March 26 at 3:49 AM
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionNeuronetics’s NeuroStar wins FDA clearance for adolescents with depression
msn.com - March 25 at 10:48 PM
Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
finanznachrichten.de - March 25 at 12:07 PM
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
marketwatch.com - March 25 at 12:07 PM
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
markets.businessinsider.com - March 25 at 12:07 PM
FDA clears Neuronetics’ neurostim for adolescents with depressionFDA clears Neuronetics’ neurostim for adolescents with depression
massdevice.com - March 25 at 12:07 PM
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
globenewswire.com - March 25 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Liquidia logo

Liquidia

NASDAQ:LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Sensus Healthcare logo

Sensus Healthcare

NASDAQ:SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
STRATA Skin Sciences logo

STRATA Skin Sciences

NASDAQ:SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.